Glaxo and Amgen Terminate Agreement - Analyst Blog

By
A A A

In an 8K filing, Amgen Inc. ( AMGN ) announced the termination of its agreement with GlaxoSmithKline ( GSK ) related to the commercialization of Prolia (denosumab) for osteoporosis in certain countries. Investors reacted negatively to the news with both Amgen and Glaxo shares falling 1.47% and 0.53%, respectively.

Original Agreement

As per the original agreement, entered in Jul 2009, both Glaxo and Amgen agreed to share the commercialization responsibility of denosumab for the postmenopausal osteoporosis (PMO) indication in Europe, Australia, New Zealand and Mexico. Amgen retained rights to the drug (for both PMO and oncology) in the U.S. and Canada and for all oncology indications in Europe and certain other countries.

In some countries like China, Brazil, India and South Korea, where Amgen did not have a commercial presence, Glaxo gained the right to market the drug for all indications.

Terms of Deal Termination

As per the terms of the termination agreement, Glaxo will be relieved of all commercial activities in all the countries covered by it under the 2009 agreement, except for Australia, by the end of this year. Amgen will regain rights to Prolia in these countries. In exchange, Amgen will make an initial payment and specific milestone payments of $275 million over the transition period. Additionally, Amgen will reimburse costs of up to $15 million incurred by Glaxo during this transition period.

However, we note that the termination agreement excludes the agreement related to the commercialization of denosumab for all indications in certain countries.

While Glaxo carries a Zacks Rank #4 (Sell), Amgen sports a Zacks Rank #1 (Strong Buy). Investors may also consider other Zacks Rank #1 stocks like Alexion Pharmaceuticals, Inc. ( ALXN ) and Alkermes ( ALKS ).



ALKERMES INC (ALKS): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: PMO , ALKS , ALXN , AMGN , GSK

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com